This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lièvre, A. Articles by Laurent-Puig, P. Search for Related Content PubMed PubMed Citation Articles by Lièvre, A. Articles by Laurent-Puig, P. Social Bookmarking                            What's this?

Clinical Value of Mitochondrial Mutations in Colorectal Cancer

From the Institut National de Santé et de la Recherche Médicale (INSERM) U490, Laboratoire de Toxicologie Moléculaire; Pôle de Cancérologie, Hôpital Européen Georges Pompidou, Paris; Centre Hospitalier Universitaire (CHU) Dijon, Service d'Anatomo-Pathologie; INSERM Equipe Mixte INSERM (EMI) 0106, CHU, Registre Bourguignon des Tumeurs; Centre de Pathologie, Rue Nicolas Bornier; Centre Georges François Leclerc, Service d'Anatomo-Pathologie, Dijon, France

Address reprint requests to Pierre Laurent-Puig, INSERM U490 Laboratoire de Toxicologie Moléculaire, 45 Rue des Saints Pères, 75006 Paris, France; e-mail: pierre.laurent-puig{at}biomedicale.univ-paris5.fr

PURPOSE: Prognostic factors that could select high-risk recurrence colorectal cancer patients and predict chemosensitivity are needed. Since mutations of mitochondrial DNA (mtDNA) have been described in different types of cancers and since they may play a role in response to anticancer agents, we investigated in a population-based series of colorectal cancer patients the clinical value of mtDNA mutations.

PATIENTS AND METHODS: The displacement loop (D-loop) region of mtDNA was sequenced on a series of 365 patients recorded in the Digestive Cancer Registry of Côte-d'Or (France) between 1998 and 2000. Clinicopathologic characteristics were correlated to the presence of a D-loop mutation. Survival rates were compared with the log-rank test. A multivariate survival analysis was performed.

RESULTS: D-loop mutations were found in 38.3% of the tumors. The 3-year survival rate was 53.5% in patients with D-loop mutation versus 62.1% in patients without (P = .05). After adjustment for age, stage, and microsatellite instability status, the relative risk of death in patients with D-loop mutation was 1.40 (95% CI, 1.02 to 1.93; P = .034) as compared with those without. In stage III colon cancers, adjuvant chemotherapy was beneficial only for patients without D-loop mutation (3-year survival, 78.3% v 45.4%, P < .02). In those with D-loop mutation who received adjuvant chemotherapy, the relative risk of death was 4.30 (95% CI, 1.23 to 15.00; P < .02).

CONCLUSION: The D-loop region is a hotspot for somatic mutations in colorectal tumors. Moreover, presence of tumor D-loop mutation appears to be a factor of poor prognosis in colorectal patients and a factor of resistance to fluorouracil-based adjuvant chemotherapy in stage III colon cancers.

Supported by L'Association de Recherche Contre le Cancer (ARC No. 3329); La Société Nationale Française de Gastroentérologie; La Region Ile de France, La Fondation de France, Paris, France.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Ye, Y.-T. Gao, W. Wen, J. P. Breyer, X. O. Shu, J. R. Smith, W. Zheng, and Q. Cai Association of Mitochondrial DNA Displacement Loop (CA)n Dinucleotide Repeat Polymorphism with Breast Cancer Risk and Survival among Chinese Women Cancer Epidemiol. Biomarkers Prev., August 1, 2008; 17(8): 2117 - 2122. [Abstract] [Full Text] [PDF]

				W.-Y. Hung, J.-C. Lin, L.-M. Lee, C.-W. Wu, L.-M. Tseng, P.-H. Yin, C.-W. Chi, and H.-C. Lee Tandem duplication/triplication correlated with poly-cytosine stretch variation in human mitochondrial DNA D-loop region Mutagenesis, March 1, 2008; 23(2): 137 - 142. [Abstract] [Full Text] [PDF]

				G. Gasparre, A. M. Porcelli, E. Bonora, L. F. Pennisi, M. Toller, L. Iommarini, A. Ghelli, M. Moretti, C. M. Betts, G. N. Martinelli, et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors PNAS, May 22, 2007; 104(21): 9001 - 9006. [Abstract] [Full Text] [PDF]

				L. Jacobs, M. Gerards, P. Chinnery, J. Dumoulin, I. de Coo, J. Geraedts, and H. Smeets mtDNA point mutations are present at various levels of heteroplasmy in human oocytes Mol. Hum. Reprod., March 1, 2007; 13(3): 149 - 154*. [Abstract] [Full Text] [PDF]

				S. Zhou, K. Kassauei, D. J. Cutler, G. C. Kennedy, D. Sidransky, A. Maitra, and J. Califano An Oligonucleotide Microarray for High-Throughput Sequencing of the Mitochondrial Genome J. Mol. Diagn., September 1, 2006; 8(4): 476 - 482. [Abstract] [Full Text] [PDF]

				D. Chen, Z. Yu, Z. Zhu, and C. D. Lopez The p53 Pathway Promotes Efficient Mitochondrial DNA Base Excision Repair in Colorectal Cancer Cells. Cancer Res., April 1, 2006; 66(7): 3485 - 3494. [Abstract] [Full Text] [PDF]